CREDORAX
20.7.2021 13:15:06 CEST | Business Wire | Press release
Leading smart payments provider and merchant acquiring bank, Credorax, has announced it is upping the ante in the world of fraud protection and chargeback mitigation by launching a cutting-edge solution to preventing chargebacks.
Credorax’s Chargeback PREVENTION marks a landmark partnership with Ethoca (owned by Mastercard), the leading, global provider of collaboration-based technology, and Verifi (a Visa solution), the leading provider of transaction risk management services for card-not-present merchants.
Merchants can now take control of their chargebacks by preventing chargebacks before they are initiated. Credorax’s innovative service offers merchants the ability to create rules that automate refunds or issue a manual refund after receiving an alert – both stop disputes from escalating to chargebacks.
Chargeback PREVENTION is part of the Credorax Risk Management suite and protects merchants from fraud and chargebacks through every stage of the transaction lifecycle. Credorax’s unique solution seamlessly combines the ingenuity of machine learning intelligence and intuitive data analysis to continually improve its fraud detection algorithm. It can accurately detect legitimate and fraudulent transactions on a large scale.
Depending on individual merchant needs and risk preferences, thresholds and rules management can be changed as and when necessary, tailored to the merchant’s unique requirements. Credorax also provides dedicated training to help merchants become familiar with Credorax’s fraud and chargeback prevention tools and optimise them based on a merchant’s particular specifications.
Drawing upon data from the world’s biggest ecommerce brands, banks, and payments providers, with Credorax’s Chargeback PREVENTION , merchants can view dashboards where they can monitor transactions, specific transaction rules and view alerts, giving them a complete overview their transaction lifecycles.
Moshe Selfin, Chief Technology Officer for Credorax, commented: “Ecommerce is booming, which means fraud and chargebacks rates are also accelerating – shockingly, merchant losses to friendly fraud were estimated to amount to over $50 billion in 2020. While far from ideal, the current state of play is undoubtedly driving levels of innovation and solution like we’ve never seen before. The sheer demand for turnkey, preventative fraud management systems, like ours, coupled with the advances in AI and real-time detection has the ability to put merchants on the front foot when dealing with fraudsters – a position they’ve never really been in before.
“With access to broadest possible range of bank issuer coverage globally, merchants have never been in a stronger position to armour themselves against the high costs and reputational hits that come with such attacks.”
Credorax is a full-service payments processor and acquirer dedicated to helping merchants by using cutting-edge technology and insights to bring innovative solutions to the market. Its payment experts are available to explain in more detail how you can benefit from its chargeback management and representation services.
Moshe added: “Our vision at Credorax has always been to provide merchants with the technology they need to take advantage of the global opportunities available to them. All while being safe in the knowledge that there are proactive and preventative measures in place that will make cross-border trading a pleasure and not a pressure.
“With a robust onboarding process that allows for an ongoing customer management journey with our specialist teams all over the world and a deep understanding of the nuances of payment processing, this is an exciting milestone in our ambition to further enhance Credorax’s exciting suite of offerings.”
For more information about Credorax’s Chargeback Prevention, visit: https://learn.credorax.com/contact-us .
#ENDS#
About Credorax
Credorax is a smart payments provider and fully licensed bank providing cross-border processing for eCommerce and omni-channel payments. Our core gateway technology, SourceTM, has been developed in-house to provide a streamlined payments experience so smart, that merchants can reach their full business potential simply by better managing their payments. Credorax merchants can accept more than a hundred cards and local payment methods and get paid in their currency of choice. Our merchants also enjoy best-in-class approval rate optimisation, advanced fraud protection, business intelligence and a host of other value-added services and products adding up to a payments experience unlike any other.
To learn more, contact us at grow@credorax.com or visit www.credorax.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210720005669/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
